Demographic and Clinical Evaluation of Patients with Pancreatic Cancer in Mashhad University of Medical Sciences During 2002-2013

Author(s): Mina A. Rad, Azar Fanipakdel, Hassan Vossoughinia, Maliheh Dadgarmoghaddam, Benyamin Esmaeili, Amir H. Jafarian, Masoumeh Salari*, Abdollah Firoozi

Journal Name: Current Cancer Therapy Reviews

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Introduction: Pancreatic cancer consists of 10% of digestive tract tumors, and while rare, it is associated with high mortality. In this study, we collected the patients’ data including tumor location, metastasis, pathology type, demographic factors, risk factors, and clinical and laboratory profile at the time of diagnosis to find the relation between these factors and disease progression.

Methods: This study includes all data from real charts of patients with a definitive diagnosis of pancreatic cancer, admitted to Ghaem, Imam Reza, and Omid hospitals from 2002 to 2013. All the data which were available in lab results, exams, and patient files, were used accordingly.

Results: 348 pancreatic cancer patients entered the study. About 61.5% of the subjects were men. Mean age was 59.67±14.37 years. Main complaints were abdominal pain (42.53%), jaundice (13.79%) or both (37.07%). We found a positive history of cancer in the first-degree relatives of 3.7% of patients, with the most prevalent being gastric cancer (46.1%). Cigarette smoking (P<0.001), tobacco smoking (cigarette or hookah) (P<0.001), opium use (P<0.001), and alcohol consumption (P=0.01) were significantly higher in men rather than women. However, hookah smoking was significantly higher in women (P=0.003). The most prevalent comorbidities were diabetes mellitus (33%) and hypertension (27.8%). The most common location of pancreatic cancer was head of the pancreas (85.3%). The most common pancreatic tumor pathology was adenocarcinoma (92.8%) with the same quiet prevalence in both genders. (P=0.5), It occurred significantly more in patients over 45 years old (P<0.001). Also, 45.7% of these patients had distant metastasis and liver was the most common metastatic site (69.8%).

Conclusion: The age range was between 40 and 80 years old. The most common chief complaints were jaundice and abdominal pain. The most common tumor location was head of the pancreas. Adenocarcinoma was the most common pathology. The liver was the most common metastasis site.

Keywords: Pancreatic cancer, demographics characteristics, clinical characteristics, gastric cancer, smoking, opium, alcohol.

[1]
Pascual HM, Herrero FE, Fé CMJ, González GFJ, Torres PP, Ballesteros BF. Epidemiology and diagnosis of the pancreatic cancer. Rev Esp Enferm Dig 2004; 96(10): 714-22.
[http://dx.doi.org/10.4321/S1130-01082004001000006] [PMID: 15537378]
[2]
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016; 22(44): 9694-705.
[http://dx.doi.org/10.3748/wjg.v22.i44.9694] [PMID: 27956793]
[3]
Pandol S, Gukovskaya A, Edderkaoui M, Dawson D, Eibl G, Lugea A. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol 2012; 27(Suppl. 2): 127-34.
[http://dx.doi.org/10.1111/j.1440-1746.2011.07013.x] [PMID: 22320930]
[4]
Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010; 102(20): 1584-98.
[http://dx.doi.org/10.1093/jnci/djq366] [PMID: 20937991]
[5]
Zhang Q, Zeng L, Chen Y, et al. Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract 2016; 20168962321
[http://dx.doi.org/10.1155/2016/8962321] [PMID: 26941789]
[6]
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013; 144(6): 1252-61.
[http://dx.doi.org/10.1053/j.gastro.2013.01.068] [PMID: 23622135]
[7]
Vera R, Dotor E, Feliu J, et al. SEOM Clinical Guideline for the treatment of pancreatic cancer Clin Transl Oncol 2016; 18(12): 1172-8.
[http://dx.doi.org/10.1007/s12094-016-1586-x] [PMID: 27896637]
[8]
Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 2006; 24(1): 87-94.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02961.x] [PMID: 16803606]
[9]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[10]
Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer 2017; 123(17): 3326-34.
[http://dx.doi.org/10.1002/cncr.30739] [PMID: 28464214]
[11]
Mariotto AB, Noone AM, Howlader N, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr 2014; 2014(49): 145-86.
[http://dx.doi.org/10.1093/jncimonographs/lgu024] [PMID: 25417231]
[12]
Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. J Surg Oncol 2013; 107(1): 1-7.
[http://dx.doi.org/10.1002/jso.23149] [PMID: 22589078]
[13]
Raju RS, Coburn N, Liu N, et al. A population-based study of the epidemiology of pancreatic cancer: a brief report. Curr Oncol 2015; 22(6): e478-84.
[http://dx.doi.org/10.3747/co.22.2653] [PMID: 26715886]
[14]
Liu F, Du F, Chen X. Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer. World J Surg Oncol 2014; 12: 333.
[http://dx.doi.org/10.1186/1477-7819-12-333] [PMID: 25381564]
[15]
Sharib J, Kirkwood K. Early and accurate diagnosis of pancreatic cancer? Oncotarget 2016; 7(52): 85676-7.
[http://dx.doi.org/10.18632/oncotarget.13142] [PMID: 27829239]
[16]
Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301(24): 2553-62.
[http://dx.doi.org/10.1001/jama.2009.886] [PMID: 19549972]
[17]
Raimondi S, Maisonneuve P, Löhr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev 2007; 16(9): 1894-7.
[http://dx.doi.org/10.1158/1055-9965.EPI-07-0341] [PMID: 17855711]
[18]
McWilliams RR, Maisonneuve P, Bamlet WR, et al. Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: A pancreatic cancer case-control consortium (PanC4) analysis Pancreas 2016; 45(2): 311-6.
[http://dx.doi.org/10.1097/MPA.0000000000000392] [PMID: 26646264]
[19]
Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 2008; 393(4): 535-45.
[http://dx.doi.org/10.1007/s00423-007-0266-2] [PMID: 18193270]
[20]
Genkinger JM, Spiegelman D, Anderson KE, et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 2009; 18(3): 765-76.
[http://dx.doi.org/10.1158/1055-9965.EPI-08-0880] [PMID: 19258474]
[21]
Duell EJ. Epidemiology and potential mechanisms of tobacco smoking and heavy alcohol consumption in pancreatic cancer. Mol Carcinog 2012; 51(1): 40-52.
[http://dx.doi.org/10.1002/mc.20786] [PMID: 22162230]
[22]
Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47(13): 1928-37.
[http://dx.doi.org/10.1016/j.ejca.2011.03.003] [PMID: 21458985]
[23]
Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92(11): 2076-83.
[http://dx.doi.org/10.1038/sj.bjc.6602619] [PMID: 15886696]
[24]
Lin JC, Chan DC, Chen PJ, et al. Clinical characteristics of early onset pancreatic adenocarcinoma: a medical center experience and review of the literature. Pancreas 2011; 40(4): 638-9.
[http://dx.doi.org/10.1097/MPA.0b013e318214fe56] [PMID: 21483255]
[25]
Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 2005; 7(5): 189-97.
[http://dx.doi.org/10.1007/BF02712816] [PMID: 15960930]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [127 - 135]
Pages: 9
DOI: 10.2174/1573394715666190422123430

Article Metrics

PDF: 12
HTML: 1